Compare CRON & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRON | TBPH |
|---|---|---|
| Founded | N/A | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | N/A |
| Metric | CRON | TBPH |
|---|---|---|
| Price | $2.61 | $19.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $27.80 |
| AVG Volume (30 Days) | ★ 1.4M | 368.8K |
| Earning Date | 02-26-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.09 | ★ 0.58 |
| Revenue | ★ $132,357,000.00 | $80,327,000.00 |
| Revenue This Year | $17.63 | $70.90 |
| Revenue Next Year | $30.76 | N/A |
| P/E Ratio | ★ $27.65 | $33.66 |
| Revenue Growth | 19.00 | ★ 27.12 |
| 52 Week Low | $1.60 | $7.90 |
| 52 Week High | $3.43 | $21.03 |
| Indicator | CRON | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.15 | 50.55 |
| Support Level | $2.57 | $18.45 |
| Resistance Level | $2.74 | $19.71 |
| Average True Range (ATR) | 0.09 | 0.80 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 58.11 | 51.63 |
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).